HRP20000520A2 - 1,2,4,5-TETRADYDRO-BENZO/d/AZEPINES - Google Patents

1,2,4,5-TETRADYDRO-BENZO/d/AZEPINES

Info

Publication number
HRP20000520A2
HRP20000520A2 HR20000520A HRP20000520A HRP20000520A2 HR P20000520 A2 HRP20000520 A2 HR P20000520A2 HR 20000520 A HR20000520 A HR 20000520A HR P20000520 A HRP20000520 A HR P20000520A HR P20000520 A2 HRP20000520 A2 HR P20000520A2
Authority
HR
Croatia
Prior art keywords
chr
tetrahydro
benzo
azepin
carbonitrile
Prior art date
Application number
HR20000520A
Other languages
English (en)
Croatian (hr)
Inventor
Adam Geo
Alfred Binggeli
Hans-Peter Maerki
Vincent Mutel
Maurice Wilhelm
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HRP20000520A2 publication Critical patent/HRP20000520A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
HR20000520A 1999-08-06 2000-08-02 1,2,4,5-TETRADYDRO-BENZO/d/AZEPINES HRP20000520A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99115557 1999-08-06

Publications (1)

Publication Number Publication Date
HRP20000520A2 true HRP20000520A2 (en) 2001-06-30

Family

ID=8238742

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000520A HRP20000520A2 (en) 1999-08-06 2000-08-02 1,2,4,5-TETRADYDRO-BENZO/d/AZEPINES

Country Status (27)

Country Link
US (1) US6218385B1 (ja)
JP (1) JP3260350B2 (ja)
KR (1) KR100390116B1 (ja)
CN (1) CN1146455C (ja)
AR (1) AR025035A1 (ja)
AT (1) ATE254614T1 (ja)
AU (1) AU774485B2 (ja)
BR (1) BR0003375A (ja)
CA (1) CA2314798A1 (ja)
CO (1) CO5180625A1 (ja)
DE (1) DE60006618T2 (ja)
ES (1) ES2209728T3 (ja)
HR (1) HRP20000520A2 (ja)
HU (1) HUP0003112A3 (ja)
ID (1) ID26743A (ja)
IL (1) IL137688A0 (ja)
MA (1) MA26748A1 (ja)
NO (1) NO20003966L (ja)
NZ (1) NZ506096A (ja)
PE (1) PE20010467A1 (ja)
PL (1) PL341890A1 (ja)
RU (1) RU2240317C2 (ja)
SG (1) SG93251A1 (ja)
TR (1) TR200002298A2 (ja)
UY (1) UY26276A1 (ja)
YU (1) YU49700A (ja)
ZA (1) ZA200003927B (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051418A1 (en) * 2000-12-22 2002-07-04 F. Hoffmann-La Roche Ag Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
RU2423353C1 (ru) * 2002-12-20 2011-07-10 Глэксо Груп Лимитед Новые производные бензазепина
CN101274911B (zh) * 2003-06-17 2011-01-26 艾尼纳制药公司 用于治疗5ht2c受体相关病症的苯并氮杂卓衍生物
SI2332921T1 (sl) 2003-06-17 2016-06-30 Arena Pharmaceuticals, Inc. 8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazapin hidroklorid
WO2005042491A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042490A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
JP5270167B2 (ja) 2004-12-21 2013-08-21 アリーナ ファーマシューティカルズ, インコーポレイテッド (r)−8−クロロ−1−メチル−2,3,4,5−テトラヒドロ−1h−3−ベンザゼピン塩酸塩の結晶形
KR20130087622A (ko) * 2004-12-23 2013-08-06 아레나 파마슈티칼스, 인크. 5ht2c 수용체 조정물질 조성물 및 그의 사용 방법
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CN101466684B (zh) * 2006-04-03 2012-06-20 艾尼纳制药公司 8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的制备工艺和其相关中间体
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010510314A (ja) 2006-11-22 2010-04-02 シーサイド セラピューティクス,エルエルシー 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法
WO2008070111A2 (en) * 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2009111004A1 (en) 2008-03-04 2009-09-11 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8952197B2 (en) 2009-06-18 2015-02-10 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
KR20130112848A (ko) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. 5-ht2c 수용체 아고니스트의 제조 방법
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
SG188361A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
NZ630494A (en) 2010-09-01 2016-05-27 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment
SG188362A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
SG10201506870PA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Salts of lorcaserin with optically active acids
KR20150070249A (ko) 2012-10-09 2015-06-24 아레나 파마슈티칼스, 인크. 체중 관리 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206210A (en) * 1977-01-19 1980-06-03 Smithkline Corporation Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
CA2095213A1 (en) * 1990-11-06 1992-05-07 Jotham W. Coe Quinazoline derivatives for enhancing antitumor activity
US5241065A (en) * 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity

Also Published As

Publication number Publication date
HU0003112D0 (en) 2000-10-28
JP3260350B2 (ja) 2002-02-25
NO20003966L (no) 2001-02-07
TR200002298A3 (tr) 2001-03-21
TR200002298A2 (tr) 2001-03-21
KR20010082510A (ko) 2001-08-30
SG93251A1 (en) 2002-12-17
UY26276A1 (es) 2000-10-31
JP2001089472A (ja) 2001-04-03
CN1146455C (zh) 2004-04-21
RU2240317C2 (ru) 2004-11-20
BR0003375A (pt) 2001-03-13
DE60006618T2 (de) 2004-09-23
IL137688A0 (en) 2001-10-31
ID26743A (id) 2001-02-08
PE20010467A1 (es) 2001-04-17
US6218385B1 (en) 2001-04-17
MA26748A1 (fr) 2004-12-20
HUP0003112A2 (hu) 2002-11-28
CO5180625A1 (es) 2002-07-30
NZ506096A (en) 2002-08-28
CN1283623A (zh) 2001-02-14
AU774485B2 (en) 2004-07-01
CA2314798A1 (en) 2001-02-06
AU4897900A (en) 2001-02-08
AR025035A1 (es) 2002-11-06
DE60006618D1 (de) 2003-12-24
ES2209728T3 (es) 2004-07-01
HUP0003112A3 (en) 2003-07-28
ZA200003927B (en) 2001-02-06
YU49700A (sh) 2003-04-30
PL341890A1 (en) 2001-02-12
KR100390116B1 (ko) 2003-07-04
ATE254614T1 (de) 2003-12-15
NO20003966D0 (no) 2000-08-04

Similar Documents

Publication Publication Date Title
HRP20000520A2 (en) 1,2,4,5-TETRADYDRO-BENZO/d/AZEPINES
EP1074549B1 (en) Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
JP3398152B2 (ja) 1n−アルキル−n−アリールピリミジンアミンおよびその誘導体
US6107301A (en) 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
ES2313110T3 (es) Compuestos de cetolactama y su utilizacion.
CA2689989A1 (en) Heterocyclic compounds and uses thereof
EP1646389A1 (en) Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
JPH0597851A (ja) 窒素含有6員環複素環を結合させるアンギオテンシンii拮抗薬
JPH05140154A (ja) 置換チオフエン又はフランを組みこんだアンギオテンシンii拮抗薬
CA2296014A1 (en) Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
KR20140103996A (ko) Lrrk2 조절제로서 아미노피리미딘 유도체
ES2340941T3 (es) Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina.
EP1644342A1 (en) Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
MXPA00007661A (en) Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
CZ20002831A3 (cs) 1.2.4.5-Tetrahydrobenzo/d/azepinové deriváty, způsob jejich přípravy a jejich použití
TW200303316A (en) Substituted indolizine-like compounds and methods of use

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBC Application rejected